Comparison of Spectra Optia and COBE Spectra apheresis systems' performances for red blood cell exchange procedures

Kim, Jaehyup; Joseph, Ranjit; Matevosyan, Karén; Sarode, Ravindra

doi:10.1016/j.transci.2016.10.004

Cited by 17 publications

(31 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have described the performances of the SO device when using the RBCX technique associated (SO/DE) or not (SO) with the depletion step for patients with SCA . These studies showed similar performance of SO compared to CSP both associated and not associated with DE.…”

mentioning

confidence: 99%

Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Chronic red blood cell exchanges (RBCXs) are frequently used to prevent complications in patients with sickle cell anemia, but the scarcity of matched red blood cell packs (RBCPs) is a serious concern. The main goal of this study was to compare the number of RBCPs used during RBCXs between the Spectra Optia (SO) device (with the automatic depletion step) and the former Cobe Spectra (CSP) device. STUDY DESIGN AND METHODS The performances and safety of 300 SO sessions using the automatic depletion step (SO/DE) in 50 patients with sickle cell anemia under a chronic transfusion program over a 1‐year period were prospectively analyzed. The numbers of RBCPs saved using this protocol compared to the SO device without depletion and to the CSP device were determined. RESULTS The SO/DE protocol appeared to be safe, as only 5% and 17% of the sessions were characterized by a significant decrease in blood pressure and increase in heart rate (grade 2 adverse events), respectively. Postapheresis hematocrit and fraction of cells remaining reached expected values. The SO/DE protocol required 16% fewer RBCPs compared to SO without depletion, allowing a mean saving of 12 RBCPs per patient and per year and 13% fewer compared to CSP device. Interestingly, the saving was more important for patients with high total blood volume and/or high preapheresis hematocrit. CONCLUSION The SO/DE protocol is an efficient, safe and cost‐effective procedure for patients with sickle cell anemia under a chronic transfusion program.

show abstract

mentioning

confidence: 99%

Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…One study selected only patients with preprocedure Hct levels of more than 26% and stable hemodynamic status . A second study required a preprocedure Hct level of 23% or more and decreased the patient's Hct up to 6% during the isovolemic hemodilution phase (if baseline Hct level was 23%‐31%) or 8% (if baseline Hct level was ≥32%) . The procedures generally were well tolerated …”

Section: Resultsmentioning

confidence: 99%

Red blood cell exchange in patients with sickle cell disease—indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB

et al. 2018

View full text Add to dashboard Cite

Although a consensus as to protocol details may not be possible, there are areas of agreement in the management of these patients, for example, that it is optimal to avoid hyperviscosity and iron overload, that a target Hb S level in the range of 30% is generally desirable, and that RCE as an acute treatment for pain crisis in the absence of other acute or chronic conditions is ordinarily discouraged.

show abstract

“…The RBC exchange devices available in the United States are centrifugation‐based; they rely on the density of blood constituents for separation, whereby centrifugation of whole blood results in layers, with RBCs forming the bottom layer. The most commonly used devices are the COBE Spectra and the Spectra Optia (both from Terumo BCT), the latter of which was approved by the US Food and Drug Administration for RBC exchange in January 2014 and is expected to replace the COBE Spectra . This newer instrument provides touch‐screen controls, and its centrifuge interface adjustments are automated through high‐speed images compared with the manual adjustments required for the COBE.…”

Section: Rbc Exchange Treatment Considerationsmentioning

confidence: 99%

Vascular access for red blood cell exchange

2018

View full text Add to dashboard Cite

Red blood cell exchange is the process of removing red blood cells from a patient and replacing them with donated blood using either automated or manual techniques. Red blood cell exchange is a well‐recognized and effective therapy for many red blood cell‐related diseases, especially sickle cell disease. However, decisions regarding the best methods for vascular access are not intuitive and must account for the patient's clinical condition, complication risks, and lifestyle, especially in the context of long‐term vascular access. In this review, we discuss the recognized indications for red blood cell exchange, considerations for the selection of exchange modality and vascular access, and recommendations for the appropriate care and prevention of risks associated with vascular access.

show abstract

Comparison of Spectra Optia and COBE Spectra apheresis systems' performances for red blood cell exchange procedures

Cited by 17 publications

References 9 publications

Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients

Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients

Red blood cell exchange in patients with sickle cell disease—indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB

Vascular access for red blood cell exchange

Contact Info

Product

Resources

About